Factors influencing the progression of amyotrophic lateral sclerosis: prospective cohort study
https://doi.org/10.17650/2222-8721-2025-15-2-37-47
Abstract
Aim. Using factor analysis, identify and rank the parameters potentially influencing the course of amyotrophic lateral sclerosis (ALS) according to their significance.
Materials and methods. A prospective cohort study of 70 patients with ALS diagnosed according to the Gold Coast criteria (2020) was performed. We studied basic socio-demographic indicators, education and social status, geography of living, anamnestic data about the disease (appearance of the first symptoms, onset, etc.), clinical picture (symptoms in the main muscle groups), progression of ALSFRS-R score, environmental risk factors (including 23 features, presented in gradation from the lowest to the highest expression).
Results. The mean age of the patients was 60.62 ± 10.2 years. The predominant proportion of patients was female,
61.4 % (n = 43), the proportion of males was 38.6 % (n = 27). The mean time from onset of symptoms to inclusion in the study and questionnaire was 12 months (95 % confidence interval 9.00–21.50). Low level of education, onset from bulbar symptoms and neck muscle involvement, severity of oral automatism reflexes, difficulty in walking and standing, contact with heavy metals, occupational sports and high stress level were correlated with rapid progression of ALS, while high level of physical activity, frequent caffeine consumption, antioxidant intake, vitamin D deficiency were observed in slow progression of ALS.
Conclusion. Our data confirm that ALS is a clinically and pathogenetically heterogeneous disease, whose rate of progression is influenced by a wide range of clinical, anamnestic, and environmental factors.
About the Authors
A. Yu. Smirnova
V.A. Almazov National Medical Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
Anna Yuryevna Smirnova,
2, Akkuratova St., Saint Petersburg 197341.
D. S. Druzhinin
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Build. 2, Trubetskaya St., Moscow 119991.
T. M. Alekseeva
V.A. Almazov National Medical Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
2, Akkuratova St., Saint Petersburg 197341.
V. S. Demeshonok
V.A. Almazov National Medical Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
2, Akkuratova St., Saint Petersburg 197341.
References
1. Van Es M. A., Hardiman O., Chio A. et al. Amyotrophic lateral sclerosis. Lancet 2017;390(10107):2084–98. DOI: 10.1016/S0140-6736(17)31287-4
2. Masrori P., van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur J Neurol 2020;27(10):1918–29. DOI: 10.1111/ene.14393
3. Akçimen F., Lopez E. R., Landers J. E. et al. Amyotrophic lateral sclerosis: Translating genetic discoveries into therapies. Nat Rev Genet 2023;24(9):642–58. DOI: 10.1038/s41576-023-00592-y
4. McGuigan A., Blair H. A. Tofersen: A review in amyotrophic lateral sclerosis associated with SOD1 mutations. CNS Drugs 2025. DOI: 10.1007/s40263-025-01204-5
5. Wei Y., Zhong S., Yang H. et al. Current therapy in amyotrophic lateral sclerosis (ALS): A review on past and future therapeutic strategies. Eur J Med Chem 2024;272:116496. DOI: 10.1016/j.ejmech.2024.116496
6. Andrew A. S., Bradley W. G., Peipert D. et al. Risk factors for amyotrophic lateral sclerosis: A regional United States casecontrol study. Muscle Nerve 2021;63(1):52–9. DOI: 10.1002/mus.27085
7. Newell M. E., Adhikari S., Halden R. U. Systematic and state- of the science review of the role of environmental factors in amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease. Sci Total Environ 2022;817:152504. DOI: 10.1016/j.scitotenv.2021.152504
8. Duan Q. Q., Jiang Z., Su W. M. et al. Risk factors of amyotrophic lateral sclerosis: A global meta-summary. Front Neurosci 2023;17:1177431. DOI: 10.3389/fnins.2023.1177431
9. Goutman S. A., Savelieff M. G., Jang D. G. et al. The amyotrophic lateral sclerosis exposome: Recent advances and future directions. Nat Rev Neurol 2023;19(10):617–34. DOI: 10.1038/s41582-023-00867-2
10. Van Eijk R. P.A., de Jongh A. D., Nikolakopoulos S. et al. An old friend who has overstayed their welcome: The ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 2021;22(3–4):300–7. DOI: 10.1080/21678421.2021.1879865
11. Rooney J., Burke T., Vajda A. et al. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2017;88(5):381–5. DOI: 10.1136/jnnp-2016–314661
12. Sun C., Chen Y., Xu L. et al. Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale as a novel tool to measure disease progression. Biomedicines 2025;13:178. DOI: 10.3390/biomedicines13010178
13. Fournier C. N. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design. Neurotherapeutics 2022;19(4):1180–92. DOI: 10.1007/s13311-022-01271-2
14. Brylev L., Demeshonok V. S., Ataulina A. I. et al. Validity and reliability of the Russian version of the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). Neurol Sci 2024;45(1):187–9. DOI: 10.1007/s10072-023-06979-3
15. Babu S., Macklin E. A., Jackson K. E. et al. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2019;21(1–2):15–23. DOI: 10.1080/21678421.2019.1672750
16. Miller T., Cudkowicz M., Shaw P. J. et al. Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 2020;383(2):109–19. DOI: 10.1056/NEJMoa2003715
17. Taylor A. A., Fournier C., Polak M. et al. Pooled resource openaccess ALS clinical trials consortium. Predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2016;3(11):866–75. DOI: 10.1002/acn3.348
18. Shefner J. M., Al-Chalabi A., Baker M. R. et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020;131(8):1975–8. DOI: 10.1016/j.clinph.2020.04.005
19. Chiò A., Moglia C., Canosa A. et al. ALS phenotype is influenced by age, sex, and genetics: A population-based study. Neurology 2020;94(8):e802–10. DOI: 10.1212/WNL.0000000000008869
20. Fang T., Pacut P., Bose A. et al. Clinical and genetic factors affecting diagnostic timeline of amyotrophic lateral sclerosis: A 15-year retrospective study. Neurol Res 2024;46(9):859–67. DOI: 10.1080/01616412.2024.2362578
21. Richards D., Morren J. A., Pioro E. P. Time to diagnosis and factors affecting diagnostic delay in amyotrophic lateral sclerosis. J Neurol Sci 2020;417:117054. DOI: 10.1016/j.jns.2020.117054
22. Calvo A., Moglia C., Lunetta C. et al. Factors predicting survival in ALS: A multicenter Italian study. J Neurol 2017;264(1):54–63. DOI: 10.1007/s00415-016-8313-y
23. Sánchez-Martínez C. M., Choreño-Parra J. A., Nuñez-Orozco L. et al. A retrospective study of the clinical phenotype and predictors of survival in non-Caucasian Hispanic patients with amyotrophic lateral sclerosis. BMC Neurol 2019;19(1):261. DOI: 10.1186/s12883-019-1459-3
24. Talman P., Duong T., Vucic S. et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open 2016;6(9):e012054. DOI: 10.1136/bmjopen-2016-012054
25. Jang D. G., Dou J., Koubek E. J. et al. Metal mixtures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: a case-control study. J Neurol Neurosurg Psychiatry 2025;96(4):329–39. DOI: 10.1136/jnnp-2024–333978
26. Chapman L., Cooper-Knock J., Shaw P. J. Physical activity as an exogenous risk factor for amyotrophic lateral sclerosis: A review of the evidence. Brain 2023;146(5):1745–57. DOI: 10.1093/brain/awac470
27. Prell T., Steinbach R., Witte O. W., Grosskreutz J. Poor emotional well-being is associated with rapid progression in amyotrophic lateral sclerosis. eNeurologicalSci 2019;16:100198. DOI: 10.1016/j.ensci.2019.100198
28. Zhang L., Tang L., Xia K. et al. Education, intelligence, and amyotrophic lateral sclerosis: A Mendelian randomization study. Ann Clin Transl Neurol 2020;7(9):1642–7. DOI: 10.1002/acn3.51156
29. Fenili G., Scaricamazza S., Ferri A. et al. Physical exercise in amyotrophic lateral sclerosis: А potential co-adjuvant therapeutic option to counteract disease progression. Front Cell Dev Biol 2024;12:1421566. DOI: 10.3389/fcell.2024.1421566
30. Park D., Kwak S. G., Park J. S. et al. Can therapeutic exercise slow down progressive functional decline in patients with amyotrophic lateral sclerosis? A meta-analysis. Front Neurol 2020;11:853. DOI: 10.3389/fneur.2020.00853
31. Huin V., Blum D., Delforge V. et al. Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition. Neurobiol Dis 2024;199:106603. DOI: 10.1016/j.nbd.2024.106603
32. Eom J., Son B., Kim S. H., Park Y. Relationship between dietary total antioxidant capacity and the prognosis of amyotrophic lateral sclerosis. Nutrients 2022;14(16):3264. DOI: 10.3390/nu14163264
33. Marques Couto C., de Melo Queiroz E., Nogueira R. et al. Brazilian multicentre study on the clinical and epidemiological profiles of 1116 patients with amyotrophic lateral sclerosis and its phenotypic variants. Amyotroph Lateral Scler Frontotemporal Degener 2022;23(5–6):353–62. DOI: 10.1080/21678421.2021.2007953
34. Libonati L., Onesti E., Gori M. C. et al. Vitamin D in amyotrophic lateral sclerosis. Funct Neurol 2017;32(1):35–40. DOI: 10.11138/fneur/2017.32.1.035
35. Juntas-Morales R., Pageot N., Marin G. et al. Low 25OH vitamin Dblood levels are independently associated with higher amyotrophic lateral sclerosis severity scores: Results from a prospective study. Front Neurol 2020;11:363. DOI: 10.3389/fneur.2020.00363
36. Wang M. D., Little J., Gomes J. et al. Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology 2017;61:101–30.
37. Filippini T., Tesauro M., Fiore M. et al. Environmental and occupational risk factors of amyotrophic lateral sclerosis: A population-based case-control study. Int J Environ Res Public Health 2020;17(8):2882. DOI: 10.3390/ijerph17082882
38. Kekenadze M., Nebadze E., Kvirkvelia N. et al. Risk factors of amyotrophic lateral sclerosis in Georgia. Georgian Med News 2023;336:91–4.
39. Westeneng H. J., Debray T. P. A., Visser A. E. et al. Prognosis for patients with amyotrophic lateral sclerosis: Development and validation of a personalised prediction model. Lancet Neurol 2018;17:423–33. DOI: 10.1016/S1474-4422(18)30089-9
Review
For citations:
Smirnova A.Yu., Druzhinin D.S., Alekseeva T.M., Demeshonok V.S. Factors influencing the progression of amyotrophic lateral sclerosis: prospective cohort study. Neuromuscular Diseases. 2025;15(2):37-47. (In Russ.) https://doi.org/10.17650/2222-8721-2025-15-2-37-47
Views:
32
Email this article 